Introduction: We study the calcitonin levels measurement in the washout of FNAB needles after sampling each thyroid nodule (FNAB-CT) as an approach to calcitonin normal value in them and distinguish of MTC and to correlate with serum CT (sCT) and cytology FNAB.
Material & Methods: 109 consecutive subjects (mean age 53.7±13.4, range 1885 yr, 79.8% females, 27.5% smokers, 18.3% autoimmune thyroid disease) initially no suspicious for MTC who underwent FNAB for thyroid nodule served as study poblation (mean size 20.1±9.3 mm.) FNAB was performed in thyroid nodule and the same needle and syringe used for FNAB was washed with 1 mL of % 0.9 sodium chloride solution and sent to the laboratory for calcitonin evaluation (FNAB-CT). Both serum and washout calcitonin were measured by chemiluminescence assay (IMMULITE 2000)
Results: In patients with a thyroid nodule under evaluation, sCT were 3.07±3.22 ng/l (range 219.4 ng/l) and and FNAB-CT values 3.98±10.36 ng/l (range 297 ng/l), respectively. In 2 patients, FNAB-CT values were 10x higher than the highest values found, but cytology results were compatible with a benign thyroid lesion and papillary carcinoma; both were submitted to surgery found MTC (serum CT/FNAB-CT: 382/32.250 ng/ml, respectively) and microMTC/C-Cell hyperplasia (serum CT/FNAB-CT: 4.5/1.150 ng/ml, respectively) In the other cases FNAB-CT values not show significative correlation with any study parameters (age, sex, autoimmune thyroiditis, tobacco, BMI) except weakly with sCT (r: 0.17, P<0.04).
Conclusion: Assaying calcitonin (CT) in the wash-out fluid from fine-needle aspiration biopsies (FNAB.CT) can be an additional and precocious approach to diagnosis of MTC
Values are expressed as mean±DE and range. sCT (serum calcitonin) nCT (calcitonin in thyroid nodule FNAB-washout)
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector
|Thyroid single nodule (n=39)||2.49±1.33 (28.1)||6.36±16.3 (297)|
|Multinodular Goitre (n=42)||3.79±4.6 (219.4)||2.02±0.02 ( 22.1)|
|Cystic lesion (n=11)||4.48±5.26 (219.4)||≤2|
|Autoimmune Disease (n=16)||2.6±1.15 (26.5)||3.59±1.15 (213.2)|
|Follicular neoplasm (n=4)||2.27±0.55 (23.10)||3.95±3.0 (28.4)|
|Papillary Cancer (n=4)||≤2||≤2|
|Material hematic (n=5)||2.6±1.34 (25)||2.31±0.77 (23.9)|
05 - 09 May 2012
European Society of Endocrinology